<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000815</url>
  </required_header>
  <id_info>
    <org_study_id>CenkOzay</org_study_id>
    <nct_id>NCT04000815</nct_id>
  </id_info>
  <brief_title>Serum Levels of C Type Natriuretic Peptide in Different Reproductive Periods</brief_title>
  <acronym>CO</acronym>
  <official_title>Serum Levels of C Type Natriuretic Peptide in Reproductive Age, Perimenopausal and Postmenopausal Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Near East University, Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Near East University, Turkey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent studies have shown that C natriuretic peptide (CNP) is produced from granulosa cells,
      increasing cumulative guanosine monophosphate (cGMP) production by affecting cumulus cells
      through natriuretic peptide receptors.It has been suggested that the transport of cGMP to
      oocyte via gap junctions causes a continuous increase in cyclic adenosine monophosphate
      (cAMP) levels within the oocyte. An important role of increased cAMP levels in oocyte is
      shown to suppress meiotic progression. Deoxyribonucleic acid (DNA) studies in animals have
      shown that expression of the natriuretic peptide precursor increases during the periovulatory
      period and shows that this increase decreases rapidly after Luteinizing hormone(LH) / human
      chorionic(hCG) stimulation. Human studies have shown that after ovulation induction, the CNP
      level in follicular fluid decreases following ovulatory dose of hCG (9).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this prospective study, 60 patients are planned to recruite. Group 1 consists of 20
      healthy reproductive aged women between 18-40 years old, with regular menstruation. Group 2
      will include 20 patients in perimenopausal time period between 40-49 ages and in group 3
      there will be20 postmenopausal women.

      Age, gravida, parity and body mass index (BMI) data of all patients will be recorded. BMI is
      calculated by dividing the body weight in kilograms by the square of the height in meters.
      All patients will go under ultrasound examination by the same clinician (ACO). The number of
      antral follicles in group 1 and group 2 will be recorded. In addition, on the 2nd or 3rd day
      of menstruation, serum FSH, LH and E2 data of the patients in group 1 and 2 will be recorded.

      For the last 6 months, patients with drug use that may affect menstruation like oral
      contraceptives, patients with cardiac or renal disease and therefore drug use, causes of
      infertility other than unexplained infertility, history of ovarian surgery, presence of
      polycystic ovary syndrome, and patients with irregular menstruation will be excluded for the
      study. In addition, patients with renal, cardiac, central nervous system and endocrine
      diseases will be excluded.

      Morning fasting venous blood samples will be taken from the patients on the 2nd or 3rd day of
      the menstruation for group 1 and 2. All blood samples will be centrifuged on the day of
      collection and separated serum samples and will be kept at -80 degrees until the day of CNP
      test. Serum CNP levels of the patients will be analyzed by an enzyme‐linked immunosorbent
      (ELISA) assay for human CNP in accordance with the manufacturer's instructions (SEA721Hu,
      ELISA Kit for Human CNP, Wuhan USCN Business Co., Ltd., Cloud-Clone Corp., CCC, USA).

      Data will be analyzed using Statistical Package for Social Sciences software (SPSS v15, SPSS
      Inc, Chicago, IL, USA). The variables will be investigated using visual and analytical
      methods (histograms, homogeneity of variances test, Kolmogorov-Simirnov/Shapiro-Wilk's test)
      to determine whether or not they are normally distributed. Patient demographics and CNP
      values will be presented as median ± interquartile range. Gravida and parity will be
      demonstrated by frequency distribution. The correlation coefficients and their significance
      will be calculated using the Spearman test. P-values less than 0.05 will be regarded as
      statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 24, 2019</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 9, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>In this study, there are three groups. Group 1:Women between 18-40 age, Group 2:Perimenopausal women (40-49 years), Group 3: Postmenopausal women.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum C Type Natriuretic Peptide Levels</measure>
    <time_frame>Second or Third Day of Menstruation</time_frame>
    <description>The comparison of serum levels of C type natriuretic peptide among different age groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2</measure>
    <time_frame>Second or Third Day of Menstruation</time_frame>
    <description>Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2</measure>
    <time_frame>Second or Third Day of Menstruation</time_frame>
    <description>Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2</measure>
    <time_frame>Second or Third Day of Menstruation</time_frame>
    <description>Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Serum CNP Levels</condition>
  <condition>Healthy Reproductive Age Women</condition>
  <condition>Healthy Perimenopausal Women</condition>
  <condition>Healthy Postmenopausal Women</condition>
  <arm_group>
    <arm_group_label>Reproductive age women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The healthy women between 18-40 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perimenopausal women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The healthy women between 40-49 years old.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal women</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The healthy women that has been in to menopause more than a year</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>C Type Natriüretic Peptide</intervention_name>
    <description>C Type Natriuretic Peptide will be measured with elisa method</description>
    <arm_group_label>Perimenopausal women</arm_group_label>
    <arm_group_label>Postmenopausal women</arm_group_label>
    <arm_group_label>Reproductive age women</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Regular cyclic menstruation for reproductive age group

        Exclusion Criteria:

          -  No systemic disease(cardiac, renal...etc)

          -  Smoking

          -  Drug usage

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Female participants will be included</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Özay</last_name>
    <role>Principal Investigator</role>
    <affiliation>Near East University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Near East University Faculty of Medicine</name>
      <address>
        <city>Nicosia</city>
        <zip>99138</zip>
        <country>Cyprus</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cyprus</country>
  </location_countries>
  <reference>
    <citation>Zhang M, Su YQ, Sugiura K, Xia G, Eppig JJ. Granulosa cell ligand NPPC and its receptor NPR2 maintain meiotic arrest in mouse oocytes. Science. 2010 Oct 15;330(6002):366-9. doi: 10.1126/science.1193573.</citation>
    <PMID>20947764</PMID>
  </reference>
  <reference>
    <citation>Norris RP, Ratzan WJ, Freudzon M, Mehlmann LM, Krall J, Movsesian MA, Wang H, Ke H, Nikolaev VO, Jaffe LA. Cyclic GMP from the surrounding somatic cells regulates cyclic AMP and meiosis in the mouse oocyte. Development. 2009 Jun;136(11):1869-78. doi: 10.1242/dev.035238.</citation>
    <PMID>19429786</PMID>
  </reference>
  <reference>
    <citation>Vaccari S, Weeks JL 2nd, Hsieh M, Menniti FS, Conti M. Cyclic GMP signaling is involved in the luteinizing hormone-dependent meiotic maturation of mouse oocytes. Biol Reprod. 2009 Sep;81(3):595-604. doi: 10.1095/biolreprod.109.077768. Epub 2009 May 27.</citation>
    <PMID>19474061</PMID>
  </reference>
  <reference>
    <citation>Tsafriri A, Chun SY, Zhang R, Hsueh AJ, Conti M. Oocyte maturation involves compartmentalization and opposing changes of cAMP levels in follicular somatic and germ cells: studies using selective phosphodiesterase inhibitors. Dev Biol. 1996 Sep 15;178(2):393-402.</citation>
    <PMID>8812137</PMID>
  </reference>
  <reference>
    <citation>Thomas RE, Armstrong DT, Gilchrist RB. Differential effects of specific phosphodiesterase isoenzyme inhibitors on bovine oocyte meiotic maturation. Dev Biol. 2002 Apr 15;244(2):215-25.</citation>
    <PMID>11944932</PMID>
  </reference>
  <reference>
    <citation>Nogueira D, Albano C, Adriaenssens T, Cortvrindt R, Bourgain C, Devroey P, Smitz J. Human oocytes reversibly arrested in prophase I by phosphodiesterase type 3 inhibitor in vitro. Biol Reprod. 2003 Sep;69(3):1042-52. Epub 2003 May 28.</citation>
    <PMID>12773402</PMID>
  </reference>
  <reference>
    <citation>Lee KB, Zhang M, Sugiura K, Wigglesworth K, Uliasz T, Jaffe LA, Eppig JJ. Hormonal coordination of natriuretic peptide type C and natriuretic peptide receptor 3 expression in mouse granulosa cells. Biol Reprod. 2013 Feb 21;88(2):42. doi: 10.1095/biolreprod.112.104810. Print 2013 Feb.</citation>
    <PMID>23255339</PMID>
  </reference>
  <reference>
    <citation>Hiradate Y, Hoshino Y, Tanemura K, Sato E. C-type natriuretic peptide inhibits porcine oocyte meiotic resumption. Zygote. 2014 Aug;22(3):372-7. doi: 10.1017/S0967199412000615. Epub 2013 Jan 18.</citation>
    <PMID>23331536</PMID>
  </reference>
  <reference>
    <citation>Kawamura K, Cheng Y, Kawamura N, Takae S, Okada A, Kawagoe Y, Mulders S, Terada Y, Hsueh AJ. Pre-ovulatory LH/hCG surge decreases C-type natriuretic peptide secretion by ovarian granulosa cells to promote meiotic resumption of pre-ovulatory oocytes. Hum Reprod. 2011 Nov;26(11):3094-101. doi: 10.1093/humrep/der282. Epub 2011 Aug 23.</citation>
    <PMID>21865234</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 22, 2019</study_first_submitted>
  <study_first_submitted_qc>June 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <results_first_submitted>January 24, 2020</results_first_submitted>
  <results_first_submitted_qc>March 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 11, 2020</results_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Near East University, Turkey</investigator_affiliation>
    <investigator_full_name>Ali Cenk</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>c type natriuretic peptide</keyword>
  <keyword>duration of menopause</keyword>
  <keyword>menstrual cycle</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Natriuretic Peptide, C-Type</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Only the name of study</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 21, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT04000815/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>For the last 6 months, patients with drug use that may affect menstruation like oral contraceptives, patients with cardiac or renal disease and therefore drug use, causes of infertility other than unexplained infertility, history of ovarian surgery, presence of polycystic ovary syndrome, and patients with irregular menstruation.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reproductive Age Women</title>
          <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="P2">
          <title>Perimenopausal Women</title>
          <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="P3">
          <title>Postmenopausal Women</title>
          <description>The healthy women that has been in to menopause more than a year
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Right ovarian cyst occured</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hypertension occured on follow up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reproductive Age Women</title>
          <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="B2">
          <title>Perimenopausal Women</title>
          <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="B3">
          <title>Postmenopausal Women</title>
          <description>The healthy women that has been in to menopause more than a year
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.9" spread="2.9"/>
                    <measurement group_id="B2" value="44.1" spread="2.2"/>
                    <measurement group_id="B3" value="57.7" spread="5.4"/>
                    <measurement group_id="B4" value="42.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Cyprus</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="15"/>
                    <count group_id="B2" value="15"/>
                    <count group_id="B3" value="15"/>
                    <count group_id="B4" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.3" spread="1.9"/>
                    <measurement group_id="B2" value="24.3" spread="2.4"/>
                    <measurement group_id="B3" value="27.1" spread="4.1"/>
                    <measurement group_id="B4" value="24.2" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum C Type Natriuretic Peptide Levels</title>
        <description>The comparison of serum levels of C type natriuretic peptide among different age groups</description>
        <time_frame>Second or Third Day of Menstruation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reproductive Age Women</title>
            <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
          <group group_id="O2">
            <title>Perimenopausal Women</title>
            <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
          <group group_id="O3">
            <title>Postmenopausal Women</title>
            <description>The healthy women that has been in to menopause more than a year
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
        </group_list>
        <measure>
          <title>Serum C Type Natriuretic Peptide Levels</title>
          <description>The comparison of serum levels of C type natriuretic peptide among different age groups</description>
          <units>pg/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.68" lower_limit="35.54" upper_limit="47.87"/>
                    <measurement group_id="O2" value="55.98" lower_limit="49.84" upper_limit="61.14"/>
                    <measurement group_id="O3" value="116.36" lower_limit="59.61" upper_limit="250.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.017</p_value>
            <p_value_desc>p-value is adjusted for multiple comparisons</p_value_desc>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2</title>
        <description>Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2</description>
        <time_frame>Second or Third Day of Menstruation</time_frame>
        <population>FSH and LH should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate these hormones since they do not have menstruation. Therefore in postmenopausal arm group these hormones (FSH and LH) are not studied.</population>
        <group_list>
          <group group_id="O1">
            <title>Reproductive Age Women</title>
            <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
          <group group_id="O2">
            <title>Perimenopausal Women</title>
            <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Serum CNP and Follicle Stimulating Hormone and Luteinizing Hormone Levels in Groups 1 and 2</title>
          <description>Correlations between serum CNP vs Follicle Stimulating Hormone(FSH), CNP vs Luteinizing Hormone(LH) levels in groups 1 and 2</description>
          <population>FSH and LH should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate these hormones since they do not have menstruation. Therefore in postmenopausal arm group these hormones (FSH and LH) are not studied.</population>
          <units>mIU/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Follicle Stimulating Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.28" lower_limit="4.68" upper_limit="6.01"/>
                    <measurement group_id="O2" value="13.12" lower_limit="9.15" upper_limit="16.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Luteinizing Hormone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.71" lower_limit="4.62" upper_limit="7.13"/>
                    <measurement group_id="O2" value="5.16" lower_limit="3.75" upper_limit="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Bi-variate correlation analysis</method>
            <method_desc>Bi-variate correlation analyses were performed in groups 1 and 2 between serum CNP and FSH and between serum CNP and LH using Spearman test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2</title>
        <description>Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test</description>
        <time_frame>Second or Third Day of Menstruation</time_frame>
        <population>AFC should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate AFC value since they do not have menstruation. Therefore in postmenopausal arm group AFC value is not studied.</population>
        <group_list>
          <group group_id="O1">
            <title>Reproductive Age Women</title>
            <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
          <group group_id="O2">
            <title>Perimenopausal Women</title>
            <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Serum CNP and Antral Follicle Count (AFC) in Groups 1 and 2</title>
          <description>Correlation between serum CNP and antral follicle count (AFC) in groups 1 and 2 using Spearman test</description>
          <population>AFC should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate AFC value since they do not have menstruation. Therefore in postmenopausal arm group AFC value is not studied.</population>
          <units>follicles</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="2.18"/>
                    <measurement group_id="O2" value="8.33" spread="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Bi-variate correlation</method>
            <method_desc>Spearman test was applied.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2</title>
        <description>Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women</description>
        <time_frame>Second or Third Day of Menstruation</time_frame>
        <population>Estradiol should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate this hormone since they do not have menstruation. Therefore in postmenopausal arm group this hormone is not studied.</population>
        <group_list>
          <group group_id="O1">
            <title>Reproductive Age Women</title>
            <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
          <group group_id="O2">
            <title>Perimenopausal Women</title>
            <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation Between Serum CNP and Estradiol Levels in Groups 1 and 2</title>
          <description>Correlation of CNP vs. Estradiol levels in reproductive age and perimenopausal women</description>
          <population>Estradiol should be evaluated during menstruation time period ( day 3). In postmenopausal women there is no spesific date to evaluate this hormone since they do not have menstruation. Therefore in postmenopausal arm group this hormone is not studied.</population>
          <units>pg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="33" upper_limit="59"/>
                    <measurement group_id="O2" value="22" lower_limit="16" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Bi-variate correlation analyses</method>
            <method_desc>Bi-variate correlation analyses were performed for all subjects in groups 1 and 2 between serum CNP and E2 using Spearman test.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were not assessed.</time_frame>
      <desc>Adverse events were not assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reproductive Age Women</title>
          <description>The healthy women between 18-40 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="E2">
          <title>Perimenopausal Women</title>
          <description>The healthy women between 40-49 years old.
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
        <group group_id="E3">
          <title>Postmenopausal Women</title>
          <description>The healthy women that has been in to menopause more than a year
C Type Natriüretic Peptide: C Type Natriuretic Peptide will be measured with elisa method</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The most prominent limitation of our study was the relatively small number of participants. This avoided us from using more powerful parametric tests for statistical analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr.Ali Cenk Ozay</name_or_title>
      <organization>Dr.Ali Cenk Ozay</organization>
      <phone>00905428583248</phone>
      <email>dr.alicenk@hotmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

